2026. Cutaneous Safety Profile of Nemolizumab in Moderate‑to‑Severe Atopic Dermatitis and Prurigo Nodularis: Pooled Analysis of Phase 3 Trials (ARCADIA 1&2 and OLYMPIA 1&2) Nodularis: Pooled Analysis of Phase 3 Trials (ARCADIA 1&2 and OLYMPIA 1&2). SKIN The Journal of Cutaneous Medicine. 10, 2 (Mar. 2026), s748. DOI:https://doi.org/10.25251/yghmqq47.